Cyclophilin A/CD147 Interaction: A Promising Target for Anticancer Therapy.

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cyclophilin A (CypA) possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity and regulates cellular functions via its interaction with the extracellular receptor CD147.
• The CypA/CD147 axis is implicated in inflammatory diseases, viral infections, and cancer progression through CD147-mediated signaling.

Purpose of the Study:

• To elucidate the biological roles and interaction of CypA and CD147.
• To review the involvement of the CypA/CD147 interaction in cancer pathology.
• To assess the therapeutic potential of targeting the CypA/CD147 axis in cancer treatment.

Main Methods:

• Literature review on CypA and CD147 biology and roles in cancer.
• Analysis of PPIA and BSG gene expression data from The Cancer Genome Atlas (TCGA) database across various tumor types.
• Correlation analysis between gene expression and patient prognosis (survival rate, cancer stage).

Main Results:

• Overexpression of CypA (PPIA) and CD147 (BSG) is significantly associated with poor prognosis, including lower survival rates and advanced cancer stages in multiple tumor types.
• PPIA and BSG expression levels are positively correlated in numerous cancer types.
• CypA/CD147 overexpression promotes cancer cell growth, metastasis, therapeutic resistance, and stem-like properties.

Conclusions:

• The CypA/CD147 interaction is a critical factor in cancer progression and patient outcomes.
• Targeting the CypA/CD147 axis presents a promising therapeutic strategy for improving cancer treatment efficacy.
• Further research into targeting this axis could lead to novel anti-cancer therapies.